Document is current
Any future updates will be listed below
-
Authors
Busch, Felix https://orcid.org/0000-0001-9770-8555
Hoffmann, Lena
Rueger, Christopher
van Dijk, Elon HC
Kader, Rawen https://orcid.org/0000-0001-9133-0838
Ortiz-Prado, Esteban
Makowski, Marcus R. https://orcid.org/0000-0001-8778-647X
Saba, Luca
Hadamitzky, Martin
Kather, Jakob Nikolas https://orcid.org/0000-0002-3730-5348
Truhn, Daniel https://orcid.org/0000-0002-9605-0728
Cuocolo, Renato
Adams, Lisa C.
Bressem, Keno K.
-
Funding
Funding for this research was provided by:
European Commission (101079894, 101079894, 101079894, 101079894, 101079894)
- License Information
-
More Information
Article History
Received: 11 March 2024
Accepted: 17 December 2024
First Online: 21 January 2025
Competing interests
: JNK declares consulting services for Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK, and Scailyte, Basel, Switzerland; furthermore JNK holds shares in Kather Consulting, Dresden, Germany; and StratifAI GmbH, Dresden, Germany, and has received honoraria for lectures and advisory board participation by AstraZeneca, Bayer, Eisai, MSD, BMS, Roche, Pfizer and Fresenius. DT holds shares in StratifAI GmbH, Dresden, Germany and has received honoraria for lectures by Bayer. KKB reports grants from the European Union (101079894) and Wilhelm-Sander Foundation; participation on a Data Safety Monitoring Board or Advisory Board for the EU Horizon 2020 LifeChamps project (875329) and the EU IHI Project IMAGIO (101112053); speaker Fees for Canon Medical Systems Corporation and GE HealthCare. RK receives medical consultancy fees from Odin Vision. The remaining authors declare no competing interests.
